This study elucidates the significant negative dose-response linear relationship of eGDR with ASCVD risk and the partial mediation effects of AIP, VAI, CMI, LAP, and BMI, highlighting the significance of enhancing glucose-utilizing capacity in decreasing the risk of ASCVD. The gene discussed is AIP; the disease is atherosclerosis.